N‑Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) as a Biomarker in Heart Failure With Preserved Ejection Fraction (HFpEF) Versus Heart Failure With Reduced Ejection Fraction (HFrEF): The Way Forward in the Age of Proteomics
Authors:
Open Access
- 8 October 2025
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e94162
Abstract
Heart failure (HF) encompasses a spectrum of clinical syndromes with substantial global morbidity and mortality, primarily linked to coronary artery disease. Affecting over 37 million individuals worldwide, its prevalence increases with age. HF is classified into three major categories: heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and the intermediate phenotype, heart failure with mid-range ejection fraction (HFmrEF). Despite similar symptomatology, differentiating HFpEF from HFrEF remains challenging, particularly through biomarker evaluation. The diagnostic and prognostic roles of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are well established; however, an unmet need persists in accurately distinguishing HFpEF from HFrEF, as NT-proBNP levels are often influenced by age, renal function, and obesity, which confound its interpretation in HFpEF. This review uniquely integrates current evidence delineating the biomarker’s pathophysiological underpinnings, clinical thresholds, and predictive capacities across HF phenotypes, while contrasting its limitations and interpretive nuances in real-world practice. For instance, while elevated NT-proBNP levels in HFrEF strongly correlate with ventricular dysfunction severity and guide therapy initiation, their diagnostic specificity in HFpEF is reduced, often necessitating adjunctive imaging or additional biomarkers for confirmation. Advances in proteomics are reshaping biomarker discovery, enabling the identification of novel cardiac stress markers such as soluble ST2 and growth differentiation factor-15 (GDF-15), which complement NT-proBNP by reflecting distinct molecular pathways of myocardial remodeling and inflammation. Although NT-proBNP remains the gold standard for prognostic assessment and risk stratification in HF, its diagnostic performance, particularly in HFpEF, must be interpreted within the broader biomarker landscape. Future directions should emphasize proteomic integration and multimarker strategies to achieve precision-based HF phenotyping and improved therapeutic outcomes.Keywords
This publication has 99 references indexed in Scilit:
- Impact of Natriuretic Peptide Polymorphisms on Diastolic and Metabolic Function in a Populational Cohort: Insights from the STANISLAS CohortESC Heart Failure, 2021
- Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association ( HFA ), European Society of Cardiology ( ESC )European Journal of Heart Failure, 2021
- Biomarkers for the diagnosis and management of heart failureHeart Failure Reviews, 2021
- Heart Failure After Myocardial Infarction: Incidence and PredictorsESC Heart Failure, 2020
- Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart FailureJAMA Cardiology, 2020
- Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide ConcentrationsEuropean Journal of Heart Failure, 2019
- Epidemiology and One-Year Outcomes in Patients With Chronic Heart Failure and Preserved, Mid-Range and Reduced Ejection Fraction: An Analysis of The ESC Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2017
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Epidemiology of Heart Failure: The Prevalence of Heart Failure and Ventricular Dysfunction in Older Adults Over Time. a Systematic ReviewEuropean Journal of Heart Failure, 2016
- Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesionsCell and tissue research, 2004